Bayer/Immune Response to co-develop gene therapy for hemophilia A.
Executive Summary
BAYER/IMMUNE RESPONSE HEMOPHILIA A GENE THERAPY COLLABORATION is worth $10 mil. in up-front funding to Immune Response and could be worth up to $100 mil. in development and commercialization costs, the Carlsbad, Calif.-based company estimated. Under a co-development agreement announced July 9, Immune Response will receive a $6 mil. license fee, a $4 mil. equity investment, research funding for the hemophilia A program, milestone payments and royalties on future product sales.